Our finding that β-Catenin plays a pivotal role in mediating PSG expression downstream of ERG and mutant p53 suggests that β-Catenin is a legitimate therapeutic target of ERG fusion- and p53 GOF mutant-positive PCa. This evidence concerns the gene PSG5 and posterior cortical atrophy.